Current use of vena cava filters in the treatment of venous trombembolism

Miroslav Solař

Interv Akut Kardiol. 2005;4(3):131  

SUBANALYSIS OF THE IMPACT OF PRIMARY PCI ON THE LEFT VENTRICULAR FUNCTION IN ANTERIOR STE-AMI

Petr Kala, Martin Poloczek, Miroslav Vytiska, Tomáš Brychta, Petr Neugebauer, Otakar Boček, Petr Jeřábek, Jiří Pařenica

Interv Akut Kardiol. 2005;4(3)

At present, primary PCI is the method of choice in the treatment of acute myocardial infarction with ST elevations (STE-AMI). Aim: To assess the influence of mechanical reperfusion on acute changes of the left ventricular systolic function assessed angiographically and to find the main related factors. Methods: Prospective observation study of 83 adult patients with a mean age of 61,6 ± 11 years treated with primary PCI up to 12 hours from STE-AMI onset who completed follow-up according to the project of LV remodeling in the period from 1 January 2002 to 30 October 2004. The main inclusion criterion was STE-AMI of the anterior wall and the main...

PRIMARY SUCCESS AND MID-TERM EFFECT OF PERCUTANEOUS CORONARY INTERVENTION IN DIABETICS WITH THE HISTORY OF CORONARY ARTERY BYPASS GRAFTING; COMPARISON WITH NONDIABETICS

Miroslav Brtko, Josef Šťásek, Pavel Polanský, Josef Bis, Dušan Černohorský, Jan Vojáček, Pavel Červinka

Interv Akut Kardiol. 2005;4(3):142-147  

Background: In patients with the history of coronary artery bypass grafting (CABG) with recurrent angina pectoris (AP) reoperation is more risky than primary operation. Percutaneous coronary intervention (PCI) is a less risky method of treatment of these patients. Sparse data are available on primary success and effectiveness of PCI in diabetics after CABG. Aim of the study: To compare primary success and effectiveness of PCI in diabetics and nondiabetics with the history of CABG in mid-term follow-up. Methods: In a prospective study 130 consecutive patients with the recurrence of AP after CABG were treated by PCI. The patients were divided into two...

NEW DATA ON CLOPIDOGREL - THE CLARITY-TIMI 28, COMMIT-CCS2 AND ARMYDA-2 TRIALS

MUDr. Miloslav Tejc, Ota Hlinomaz

Interv Akut Kardiol. 2005;4(3):154-158  

Two new trials (CLARITY and COMMIT) have brought new data on the role of clopidogrel in treatment of patients with ST-elevation-myocardial infarction (STEMI). The ARMYDA-2 trial is concerned with optimalization of clopidogrel loading dose before intervention. In the CLARITY trial, the addition of clopidogrel to aspirin plus thrombolysis improved the patency rate of the infarct-related artery and reduced ischaemic complications in STEMI patients. The COMMIT trial has shown a positive effect of early administered clopidogrel on mortality of STEMI patients. In the ARMYDA-2 trial, pretreatment with a 600 mg loading dose of clopidogrel 4 to 8 hours before...

AORTIC DISSECTION

Jiří Vejvoda, David Alan, Petr Ošťádal

Interv Akut Kardiol. 2005;4(3):159-165  

Aortic dissection (AD) is a rare disease with the incidence of approximately 30 cases per million people per year. Although AD is uncommon, it becomes among serious, life-threatening diseases and its outcome is frequently fatal prior to diagnosis. Chest pain is the most common symptom of AD, many patients may, however, develop various other symptoms secondary to the involvement of specific organ systems. Also physical findings are usually not efficient for accurate and rapid diagnosis of AD. In suspicion for AD, imaging methods are essential for confirmation of this diagnosis; computer tomography (CT) scanning or transesophageal echocardiography (TEE),...

Nitrates at the beginning of the 3rd millenium

Tomáš Hodač

Interv Akut Kardiol. 2005;4(3):166-168  

Although nitrates have a long history, they still continue to be a significant group of commonly used cardiovasclar drugs. Especially in the treatment of heart failure in the terrain of ischaemic heart disease, where they play an irreplaceable role. Most of the knowledge regarding the effects and administration of these drugs is generally known. However, there exist certain interesting and important aspects that are forgotten with time.

Vineberg‘s procedure - 31 years after

Vladimír Rozsíval, Jiří Kvasnička, Čestmír Reček

Interv Akut Kardiol. 2005;4(3):179  

AN UNUSUAL COURSE OF PULMONARY EMBOLISM

Jan Mrózek, Sabina Krištofová, Martin Křístek, Petr Černý

Interv Akut Kardiol. 2005;4(3):171-174  

The authors report a case of a female patient with an unusual course of pulmonary embolism, presenting with recurrent syncopes with bradycardia. An intracardiac embolus impacted in the patents oval foramen was found on transoesophageal echocardiography examination. The syncopes resolved and the intracardiac thromboembolus decreased after the introduction of a caval filter and with anticoagulation treatment.

PERICARDIAL TAMPONADE AS RARE COMPLICATION OF COMBINED ANTICOAGULANT AND ANTIPLATELATE THERAPY DURING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME

Jiří Koza, Michal Čepelák, Jan Pešek, Viktor Zlocha

Interv Akut Kardiol. 2005;4(3):176-178  

Percutaneous coronary intervention became a common management of ischaemic heart disease. However with the increasing number of operations the probability of occurrence of some rare procedure complications increases as well. Our case report warns about possible occurrence of pericardial tamponade after uncomplicated coronary intervention, probably based on combined antiplatelet and anticoagulant treatment in the patient with no previous pericardial affection before the procedure.

Left ventricular function in patients with primary PCI. What we know, what we think we know and what we do not know

Jan Vojáček

Interv Akut Kardiol. 2005;4(3):138-139  

Percutaneous coronary intervention in diabetics after coronary artery bypass grafting

Ota Hlinomaz

Interv Akut Kardiol. 2005;4(3):140-141  

Letters

-

Interv Akut Kardiol. 2005;4(3):180-182  

Report from Congress of the Czech Society of Cardiology (Brno 2005) - Arrhythmology

Renata Krausová

Interv Akut Kardiol. 2005;4(3):183  

Report from Congress of the Czech Society of Cardiology (Brno 2005) - International Cardiology

Petr Kala, Petr Neugebauer

Interv Akut Kardiol. 2005;4(3):184  

15th PRAGUE Workshop on Interventional Cardiology - INTERCATH 2005

MUDr. Michael Želízko CSc

Interv Akut Kardiol. 2005;4(3):185-186  

SCD-HeFT TRIAL (THE SUDDEN CARDIAC DEATH IN HEART FAILURE TRIAL) - REAL INFLUENCE ON MORTALITY IN PATIENTS WITH HEART FAILURE?

Miloš Táborský, Petr Neužil

Interv Akut Kardiol. 2005;4(3):169-170  

Sudden cardiac death from cardiac causes remains a leading cause of death among the patients with congestive heart failure. The primary end point of the trial was death from any cause comparing treatment with amiodarone or an implantable cardioverter-defibrillator against placebo. In patients with NYHA class II or III chronic heart failure and LV EF < 0.35 amiodarone did not have effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 %.